<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457613</url>
  </required_header>
  <id_info>
    <org_study_id>PP05</org_study_id>
    <nct_id>NCT00457613</nct_id>
  </id_info>
  <brief_title>Effects of Alkaline Phosphatase on Renal Function in Septic Patients</brief_title>
  <official_title>Effects of Alkaline Phosphatase on Renal Function in Patients With Severe Sepsis or Septic Shock.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Septic shock is the most common cause of death in patients requiring intensive care. The&#xD;
      kidney is one of the first organs to fail, stressing the importance to search for clinical&#xD;
      interventions that may protect the kidneys during sepsis.&#xD;
&#xD;
      Alkaline phosphatase functions as a host defence molecule and is present in many cells and&#xD;
      organs (e.g. intestine, placenta, liver, kidney and bone). Alkaline phosphatase has a dual&#xD;
      mode of action. First, it binds to and, subsequently, dephosphorylates lipopolysaccharide&#xD;
      (LPS). Second, the enzymatic reaction product monophosphoryl-LPS is a non-toxic substance for&#xD;
      mammals which acts as a partial antagonist on the LPS receptor complex. In several animal&#xD;
      studies, administration of alkaline phosphatase attenuates the inflammatory response and&#xD;
      reduces mortality.&#xD;
&#xD;
      It is unknown whether these results can be extrapolated to septic patients . We studied the&#xD;
      effects of alkaline phosphatse administration on kidney damage and function in patients with&#xD;
      severe sepsis or septic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date>March 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers of kidney damage</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>kidney function</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>markers of inflammation</measure>
  </primary_outcome>
  <enrollment>15</enrollment>
  <condition>Severe</condition>
  <condition>Septic</condition>
  <condition>Shock</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Proven or suspected Gram-negative bacterial infection&#xD;
&#xD;
          -  Two out of four Systemic Inflammatory Response Syndrome (SIRS) criteria existing for&#xD;
             less than 24 h&#xD;
&#xD;
          -  Acute onset of end-organ dysfunction in the preceding 12 h&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with alkaline phosphatase&#xD;
&#xD;
          -  Known allergy for cow milk&#xD;
&#xD;
          -  Probable death within 24 h&#xD;
&#xD;
          -  Chronic renal failure requiring hemodialysis or peritoneal dialysis&#xD;
&#xD;
          -  Acute pancreatitis with no established source of infection&#xD;
&#xD;
          -  HIV seropositive&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Confirmed Gram-positive or fungal sepsis&#xD;
&#xD;
          -  Treatment with immunosuppressants including high doses of glucocorticosteroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Pickkers, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2006</verification_date>
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <last_update_submitted>April 5, 2007</last_update_submitted>
  <last_update_submitted_qc>April 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2007</last_update_posted>
  <keyword>alkaline phosphatase</keyword>
  <keyword>sepsis</keyword>
  <keyword>kidney function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

